Chart, page-694

BD1 has four key programs in commercial development:

hTERT:

Animmunocytochemistry (ICC) assay that detects hTERT, a component of telomerase,which is upregulated in most human epithelial cancers. The initial commercialapplication of the hTERT test is as an adjunct to urine cytology, assisting inthe diagnosis of bladder cancer.

The test is in the market and generating revenues. The product,Anti-hTERT antibody (SCD-A7) is:

· An antibody targeted against the hTERT proteincomponent of the telomerase complex.

· Listed with the FDA for sale in the USA, withexisting reimbursement in that market.

BARD1:

Abiomarker platform covering various BARD1 tumour markers including nucleicacids, proteins and autoantibodies. The first application is the BARD1autoantibody tests for early detection of ovarian, breast and lung cancers.

SIEN-NET:

Abiomarker capture platform that uses patented Molecular NETs to capture andpurify target molecules from patient samples in a scalable, rapid andcost-effective method for utilisation in high throughput laboratories. TheSIEN-NET platform enables the Company to access the rapidly growing liquidbiopsy market

SubB2M:

A pan-cancer probe that is specific for cancercells and has the potential to complement other technologies and biomarkers todetect cancer using a range of testing modalities such as liquid biopsies,immunoassays, circulating tumor cell assays and PET imaging.

BD 1 attracted three key strategic biotech investors(see ASX: 19 June 2019), Kidder Williams' David Williams, EFM Asset Management's Jeff Emmanuel and biotechnology institutional investor, The Merchant Opportunities Fund, who have a proven track record of identifying promising early-stage life sciences companies.

David Williams is the Managing Director ofKidder Williams and has over 30 years' experience providing mergers andacquisitions, and capital raising advice. David is also the Chairman of MedicalDevelopments International (MVP), Rate My Agent (RMY) and PolyNovo (PNV).

Jeff Emmanuel is a Director of global equitiesasset manager, EFM Asset Management. Jeff's speciality is identifying growthopportunities that present themselves as 'emerging winners,' backing theindividuals behind what he identifies as a successful business. His investmentsinclude PolyNovo, BARD1 (BD1) and Sienna Cancer Diagnostics (SDX).

Finally, The Merchant Opportunities Fund is aboutique fund with a particular focus on long-term strategic investments in theAustralian biotechnology industry.